Serum hyaluronan as a disease marker

Annals of Medicine

Volumn 28, Issue 3, 1996, Pages 241-253

  Laurent, Torvard C ^a   Laurent, Ulla B G ^a   Fraser, J Robert E ^b  

^a UPPSALA UNIVERSITY   (Sweden)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Connective tissue; Joint disease; Liver cirrhosis; Liver transplants; Mesothelioma; Septicaemia; Wilms' tumour

Indexed keywords

BIOCHEMICAL MARKER; HYALURONIC ACID; POLYSACCHARIDE;

ARTHROPATHY; BLOOD LEVEL; CONNECTIVE TISSUE; ENDOTHELIUM CELL; HUMAN; LIVER CIRRHOSIS; LIVER CLEARANCE; LIVER DISEASE; MESOTHELIOMA; NEPHROBLASTOMA; PHYSICAL ACTIVITY; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SEPTICEMIA; WERNER SYNDROME;

EID: 0029973179     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.3109/07853899609033126     Document Type: Review

References (160)

1. Evered D, Whelan J, eds. The Biology of Hyaluronan. Chichester: John Wiley & Sons, 1989.
2. Laurent TC, Fraser JRE. Hyaluronan. FASEB J 1992; 6: 2397-404.
3. Comper WD, Laurent TC. Physiological function of connective tissue polysaccharides. Physiol Rev 1978; 58: 255-315.
4. Knudson CB, Knudson W. Hyaluronan-binding proteins in development, tissue homeostasis, and disease. FASEB J 1993; 7: 1233-41.
5. Miller D, Stegmann R, eds. Healon (Sodium Hyaluronate): A Guide to Its Use in Ophthalmic Surgery. New York: John Wiley & Sons, 1983.
6. Adams ME, ed. Viscosupplementation: a treatment for osteoarthritis. J Rheumatol 1993; 20: Suppl 39.
7. Engström-Laurent A. Changes in hyaluronan concentration in tissues and body fluids in disease states. In: Evered D, Whelan J, eds. The Biology of Hyaluronan. Chichester: John Wiley & Sons, 1989: 233-47.
8. Engström-Laurent A, Laurent TC. Hyaluronan as a clinical marker. In: Lindh E, Thoreli JI, eds. Clinical Impact of Bone and Connective Tissue Markers. London: Academic Press, 1989: 235-52.
9. Tengblad A. Quantitative analysis of hyaluronate in nanogram amounts. Biochem J 1980; 185: 101-5.
10. Lindqvist U, Chichibu K, Delpech B, et al. Seven different assays for hyaluronan compared for clinical utility. Clin Chem 1992; 38: 127-32.
11. Laurent UBG, Laurent TC. On the origin of hyaluronate in blood. Biochem Int 1981; 2: 195-9.
12. Engström-Laurent A, Laurent UBG, Lilja K, Laurent TC. Concentration of sodium hyaluronate in serum. Scand J Clin Lab Invest 1985; 45: 497-504.
13. Lindqvist U, Laurent TC. Serum hyaluronan and aminoterminal propeptide of type III procollagen: variation with age. Scand J Clin Lab Invest 1992; 52: 613-21.
14. Tengblad A, Laurent UBG, Lilja K, et al. Concentration and molecular mass of hyaluronate in lymph and blood. Biochem J 1986; 236: 521-5.
15. Fraser JRE. Changes in the relative molecular mass of circulating hyaluronan. R Soc Med Round Table Series 1995; 36: 8-10.
16. Fraser JRE, Laurent TC, Pertoft H, Baxter E. Plasma clearance, tissue distribution and metabolism of hyaluronic acid injected intravenously in the rabbit. Biochem J 1981; 200: 415-24.
17. Bentsen KD, Henriksen JH, Laurent TC. Circulating hyaluronate: concentration in different vascular beds. Clin Sci 1986; 71: 161-5.
18. Laurent TC, Lilja K, Brunnberg L, et al. Urinary excretion of hyaluronan in man. Scand J Clin Lab Invest 1987; 47: 793-9.
19. Fraser JRE, Laurent TC, Engström-Laurent A, Laurent UBG. Elimination of hyaluronic acid from the blood stream in the human. Clin Exp Pharmacol Physiol 1984; 11: 17-25.
20. Laurent TC, Fraser JRE. Catabolism of hyaluronan. In: Henriksen JH, ed. Degradation of Bioactive Substances Physiology and Pathophysiology. Boca Raton: CRC Press, 1991: 249-65.
21. Laurent UBG, Fraser JRE, Engström-Laurent A, Reed RK, Dahl LB, Laurent TC. Catabolism of hyaluronan in the knee joint of the rabbit. Matrix 1992; 12: 130-6.
22. Fraser JRE, Kimpton WG, Laurent TC, Cahill RNP, Vakakis N. Uptake and degradation of hyaluronan in lymphatic tissue. Biochem J 1988; 256: 153-8.
23. Smedsrod, B, Pertoft H, Gustafson S, Laurent TC. Scavenger function of the liver endothelial cell. Biochem J 1990; 266: 313-27.
24. Lebel L, Gabrielsson J, Laurent TC, Gerdin B. Kinetics of circulating hyaluronan in humans. Eur J Clin Invest 1994; 24: 621-6.
25. Engström-Laurent A, Lööf L, Nyberg A, Schröder T. Increased serum levels of hyaluronate in liver disease. Hepatology 1985; 5: 638-42.
26. Frebourg T, Delpech B, Bercoff E, et al. Serum hyaluronate in liver diseases: study by enzymoimmunological assay. Hepatology 1986; 6: 392-5.
27. Lindqvist U, Engström-Laurent A, Laurent U, et al. The diurnal variation of serum hyaluronan in health and disease. Scand J Clin Lab Invest 1988; 48: 765-70.
28. Bentsen KD, Horn T, Risteli J, et al. Serum aminoterminal type III procollagen peptide and the 7S domain of type - IV collagen in patients with alcohol abuse. Relation to ultrastructural fibrosis in the acinar zone 3 and to serum hyaluronan. Liver 1987; 7: 339-46.
29. Tanikawa K. Serum markers for hepatic fibrosis and related liver pathology. Pathol Res Pract 1994; 190: 960-8.
30. Mattsson L, Lindqvist U, Weiland O, Åberg B. Serum levels of the aminoterminal propeptide of type III procollagen and hyaluronan during resolving and non-resolving posttransfusion non-A, non-B hepatitis. Scand J Infect Dis 1990; 22: 11-7.
31. Gao F, Kong XT, Wang XL. The extracellular matrix and liver disease: a study with enzymoimmunological assay. Chung Hua Nei Ko Tsa Chih 1994; 33: 109-12.
32. Guéchot J, Poupon RE, Girat P, Balkau B, Giboudeau J, Poupon R. Relationship between procollagen III aminoterminal propetide and hyaluronan serum levels and histological fibrosis in primary biliary cirrhosis and chronic viral hepatitis C. J Hepatol 1994; 20: 388-93.
33. Ramadori G, Zöhrens G, Manns M, et al. Serum hyaluronate and type III procollagen aminoterminal propeptide concentration in chronic liver disease. Relationship to cirrhosis and disease activity. Eur J Clin Invest 1991; 21: 323-30.
34. Gallorini A, Plebani M, Pontisso P, et al. Serum markers of hepatic fibrogenesis in chronic hepatitis type C treated with alfa-2A interferon. Liver 1994; 14: 257-64.
35. Guéchot J, Loria A, Serfaty L, Giral P, Giboudeau J, Poupon R. Serum hyaluronan as a marker of liver fibrosis in chronic viral hepatitis C: effect of α-interferon therapy. J Hepatol 1995; 22: 22-6.
36. Matsunaga T, Kojima J, Inoue A, Matsumiya K. Serum hyaluronate levels predict responsiveness to interferon alpha therapy in patients with chronic hepatitis C. Clin Chim Acta 1994; 229: 191-5.
37. 2a increases serum concentration of hyaluronic acid and type III procollagen aminoterminal propeptide in patients with chronic hepatitis B virus infection. Dig Dis Sci 1994; 39: 2007-13.
38. Nyberg A, Engström-Laurent A, Lööf L. Serum hyaluronate in primary biliary cirrhosis - a biochemical marker for progressive liver damage. Hepatology 1988; 8: 142-6.
39. Plebani M, Giacomini A, Floreani A, et al. Biochemical markers of hepatic fibrosis in primary biliary cirrhosis. Res Clin Lab 1990; 20: 269-74.
40. Babbs C, Haboubi NY, Mellor JM, Smith A, Rowan BP, Warnes TW. Endothelial cell transformation in primary biliary cirrhosis: a morphological and biochemical study. Hepatology 1990; 11: 723-9.
41. Nyberg A, Lindqvist U, Engström-Laurent A. Serum hyaluronan and amino-terminal propeptide of type III procollagen in primary biliary cirrhosis: relation to clinical symptoms, liver histopathology and outcome. J Int Med 1992; 231: 485-91.
42. Floreani A, Zappalà F, Mazzetto M, Naccarato R, Plebani M, Chiaramonte M. Different response to ursodeoxycholic acid (UDCA) in primary biliary cirrhosis according to severity of disease. Dig Dis Sci 1994; 39: 9-14.
43. Poupon RE, Balkau B, Guéchot J, Heintzmann F. Predictive factors in ursodeoxycholic acid-treated patients with primary biliary cirrhosis: role of serum markers of connective tissue. Hepatology 1994; 19: 635-40.
44. Trivedi P, Cheeseman P, Mowat AP. Serum hyaluronic acid in healthy infants and children and its value as a marker of progressive hepatobiliary disease starting in infancy. Clin Chim Acta 1993; 215: 29-39.
45. Calçado A, Trivedi P, Portmann B, Mowat AP. Serum concentrations of extracellular matrix components: novel markers of metabolic control and hepatic pathology in glycogen storage disease? J Ped Gastroenterol Nutr 1991; 13: 1-9.
46. Bramley PN, Rathbone BJ, Forbes MA, Cooper EH, Losowsky MS. Serum hyaluronate as a marker of hepatic derangement in acute liver damage J Hepatol 1991; 13: 8-13.
47. Fraser JRE, Engström-Laurent A, Nyberg A, Laurent TC. Removal of hyaluronic acid from the circulation in rheumatoid disease and primary biliary cirrhosis. J Lab Clin Med 1986; 107: 79-85.
48. Henriksen JH, Bentsen KD, Laurent TC. Splanchnic and renal extraction of circulating hyaluronan in patients with alcoholic liver disease. J Hepatol 1988; 6: 158-66.
49. Lindqvist U, Groth T, Lööf L, Hellsing K. A hyaluronan-loading test applied to patients with liver and joint diseases. Clin Chim Acta 1992; 210: 119-32.
50. Kropf J, Gressner AM, Tittor W. Logistic-regression model for assessing portal hypertension by measuring hyaluronic acid (hyaluronan) and laminin in serum. Clin Chem 1991; 37: 30-5.
51. Gibson PR, Fraser JRE, Brown TJ, et al. Hemodynamic and liver function predictors of serum hyaluronan in alcoholic liver disease. Hepatology 1992; 15: 1054-9.
52. Gibson PR, Fraser JRE, Colman JC, Jones PA, Jennings G, Dudley FJ. Change in serum hyaluronan: a simple index of short-term drug-induced changes in hepatic sinusoidal perfusion. Gastroenterology 1993; 105: 470-4.
53. Ueno T, Inuzuka S, Torimura T, et al. Serum hyaluronate reflects hepatic sinusoidal capillarization. Gastroenterology 1993; 105: 475-81.
54. Adams DH, Wang L, Hubscher SG, Neuberger JM. Hepatic endothelial cells. Targets in liver allograft reaction? Transplantation 1989; 47: 479-82.
55. Pollard SG, Forbes MA, Metcalfe SM, Cooper EH, Calne RY. Hyaluronic acid in the assessment of liver graft function. Transplant Proc 1990; 22: 2301-2.
56. Suehiro T, Boros P, Curtiss S, et al. Perioperative hyaluronic acid levels in orthotopic liver transplant recipient. Transplant Proc 1995; 27: 1261.
57. Michell ID, Abdulnour I, Pzybylowski G, et al. Donor hyaluronic acid and MEGX levels do not accurately predict posttransplant liver function. Transplant Proc 1993; 25: 2888-9.
58. Bronsther OL, Rao PN, Pinna A, et al. Effluent levels of hyaluronic acid can predict ultimate graft outcome after clinical liver transplantation: a prospective series. Transplant Proc 1993; 25: 1538-40.
59. Rao PN, Bronsther OL, Pinna AD, et al. Prediction of early graft function by effluent levels of hyaluronic acid in clinical liver transplantation. Transplant Proc 1993; 25: 2141-2.
60. Karayalcin K, Harrison JD, Attard A, et al. Can effluent hyaluronic acid or creatine kinase predict sinusoidal injury severity after cold ischemia? Transplantation 1993; 56: 1336-9.
61. Laurent TC, Fraser JRE, Laurent UBG, Engström-Laurent A. Hyaluronan in inflammatory joint disease. Acta Orthop Scand 1995; 66 (Suppl 266): 116-20.
62. Engström-Laurent A, Hällgren R. Circulating hyaluronate in rheumatoid arthritis: relationship to inflammatory activity and the effect of corticosteroid therapy. Ann Rheum Dis 1985; 44: 83-8.
63. Engström-Laurent A, Hällgren R. Circulating hyaluronic acid levels vary with physical activity in healthy subjects and in rheumatoid arthritis patients. Arthritis Rheum 1987; 30: 1333-8.
64. Seibel MJ, Raimann S, Lautenschläger J, Müller W. Serum-Hyaluronsäure und aminoterminales Prokollagen-III-Peptid bei entzündlichen und degenerativen Gelenkerkrankungen. Z Rheumatol 1988; 47: 98-106.
65. Hørslev-Petersen K, Bentsen KD, Engström-Laurent A, Junker P, Halberg P, Lorenzen I. Serum amino terminal type III procollagen peptide and serum hyaluronan in rheumatoid arthritis: relation to clinical and serological parameters of inflammation during 8 and 24 months' treatment with levamisole, penicillamine, or azathioprine. Ann Rheum Dis 1988; 47: 116-26.
66. Levesque H, Delpech B, Le Loet X, Deshayes P. Serum hyaluronate in rheumatoid arthritis: study by affino-immunoenzymatic assay. Br J Rheumatol 1988; 27: 445-9.
67. Chassagne P, Le Loet X, Delpech B, et al. Études des variations nycthémérales du taux sérique d'acide hyaluronique au cours de la polyarthrite rhumatoïde. Rev Rhum Mal Osteoartic 1989; 56: 775-9.
68. Konttinen YT, Saari H, Honkanen VEA, et al. Serum baseline hyaluronate and disease activity in rheumatoid arthritis. Clin Chim Acta 1990; 193: 39-48.
69. Poole AR, Witter J, Roberts N, et al. Inflammation and cartilage metabolism in rheumatoid arthritis. Arthritis Rheum 1990; 33: 790-9.
70. Goldberg RL, Huff JP, Lenz ME, Glickman P, Katz R, Thonar EJ-MA. Elevated plasma levels of hyaluronate in patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum 1991; 34: 799-807.
71. Paimela L, Heiskanen A, Kurki P, Helve T, Leirisalo-Repo M. Serum hyaluronate level as a predictor of radiologic progression in early rheumatoid arthritis. Arthritis Rheum 1991; 34: 815-21.
72. Saari H, Konttinen YT, Nordström D. Effect of joint mobilization on serum hyaluronate. Ann Med 1991; 23: 29-32.
73. Hedin P-J, Weitoft T, Hedin H, Engström-Laurent A, Saxne T. Serum concentrations of hyaluronan and proteoglycans in joint disease. Lack of association. J Rheumatol 1991; 18: 1601-5.
74. Manicourt D-H, Triki R, Fukuda K, Devogelaer J-P, Nagant de Deuxchaisnes C, Thonar EJ-MA. Levels of circulating tumour necrosis factor α and interleukin-6 in patients with rheumatoid arthritis. Relationship to serum levels of hyaluronan and antigenic keratan sulfate. Arthritis Rheum 1993; 36: 490-9.
75. Andersson Gäre B, Fasth A. Serum concentration of hyaluronan, IgM and IgA rheumatoid factors in a population based study of juvenile chronic arthritis. Scand J Rheumatol 1994; 23: 183-90.
76. Maeno N, Imanaka H, Takei S, et al. Clinical features of infantile patient with juvenile rheumatoid arthritis. Ryumachi 1994; 34: 901-7.
77. Yamada N, Uzuki M, Rikimaru A, Sakurai M, Sawai T. Increased levels of circulating hyaluronate in sera of patients with rheumatoid arthritis with special reference to joint destruction. Ryumachi 1994; 34: 752-60.
78. Månsson B, Carey D, Alini M, et al. Cartilage and bone metabolism in rheumatoid arthritis. Differences between rapid and slow progression of disease identified by serum markers of cartilage metabolism. J Clin Invest. 1995; 95: 1071-7.
79. Sharif M, George E, Shepstone L, et al. Serum hyaluronic acid level as a predictor of disease progression in osteoarthritis of the knee. Arthritis Rheum 1995; 38: 760-7.
80. Lundin Å, Engström-Laurent A, Hällgren R, Michaëlsson G. Circulating hyaluronate in psoriasis. Br J Dermatol 1985; 112: 663-71.
81. Jouzeau J-Y, Payan E, Gillet P, Péré P, Netter P, Gaucher A. Clinical significance of hyaluronan in rheumatic diseases: comment on the articles by Goldberg and Woessner. Arthritis Rheum 1992; 35: 1253-4.
82. Björk J, Kleinau S, Tengblad A, Smedegård G. Elevated levels of serum hyaluronate and correlation with disease activity in experimental models of arthritis. Arthritis Rheum 1989; 32: 306-11.
83. Goldberg RL, Rubin AS. Serum hyaluronate as a marker for disease severity in the Lactobacillus casei model of arthritis in the rat. J Rheumatol 1989; 16: 92-6.
84. Butler DM, Vitti GF, Leizer T, Hamilton JA. Stimulation of the hyaluronic acid levels of human synovial fibroblasts by recombinant human tumour necrosis factor-α, tumour necrosis factor-β (lymphotoxin), interleukin-1α, and interleukin-1β. Arthritis Rheum 1988; 31: 1281-9.
85. Van Snick J. Interleukin-6: an overview. Annu Rev Immunol 1990; 8: 253-78.
86. Pile KD, Laurent MR, Cairns DR, Chivers TK, Brooks PM. Serum IgM and IgA rheumatoid factor and hyaluronic acid in early rheumatoid arthritis. Abstracts of the XII European Congress of Rheumatology, July, 1991.
87. Pitsillides AA, Will RK, Bayliss MT, Edwards JCW. Circulating and synovial fluid hyaluronan levels. Effects of intraarticular corticosteroid on the concentration and rate of turnover. Arthritis Rheum 1994; 37: 1030-8.
88. Laurent TC, Fraser JRE. The properties and turnover of hyaluronan. In: Evered D, Whelan J, eds. Functions of the Proteoglycans. Chichester: John Wiley & Sons, 1986: 9-29.
89. The Australian Multicentre Clinical Trial Group. Sulfasalazine in early rheumatoid arthritis. J Rheumatol 1992; 19: 1672-7.
90. Bertin P, Lapicque F, Payan E, et al. Sodium naproxen: concentration and effect on inflammatory response mediators in human rheumatoid synovial fluid. Eur J Clin Pharmacol 1994; 46: 3-7.
91. Engström-Laurent A, Feltelius N, Hällgren R, Wasteson Å. Raised serum hyaluronate levels in scleroderma: an effect of growth factor-induced activation of connective tissue cells? Ann Rheum Dis 1985; 44: 614-20.
92. Hørslev-Petersen K, Ammitzbøll T, Engström-Laurent A, et al. Serum and urinary aminoterminal type III procollagen peptide in progressive systemic sclerosis: relationship to sclerodermal involvement, serum hyaluronan and urinary collagen metabolites. J Rheumatol 1988; 15: 460-7.
93. Levesque H, Baudot N, Delpech B, et al. Clinical correlations and prognosis based on hyaluronic acid serum levels in patients with progressive systemic sclerosis. Br J Dermatol 1991; 124: 423-28.
94. Scheja A, Åkesson A, Hørslev-Petersen K. Serum levels of aminoterminal type III procollagen peptide and hyaluronan predict mortality in systemic sclerosis. Scand J Rheumatol 1992; 21: 5-9.
95. Hasselbalch H, Junker P, Lisse I, Lindqvist U, Engström-Laurent A. Circulating hyaluronan in the myelofibrosis/osteomyelosclerosis syndrome and other myeloproliferative disorders. Am J Hematol 1991; 36: 1-8.
96. Faber J, Hørslev-Petersen K, Perrild H, Lorenzen I. Different effects of thyroid disease on serum levels of procollagen III N-peptide and hyaluronic acid. J Clin Endocrinol Metab 1990; 71: 1016-21.
97. Imai Y, Odajima R, Shimizu T, Shishiba Y. Serum hyaluronan concentration determined by radiometrib assay in patients with pretibial myxedema and Graves' ophthalmopathy. Endocrinol Jpn 1990; 37: 749-52.
98. Ohtsuka Y, Yamamoto K, Goto Y, et al. Localized myxedema, associated with increased serum hyaluronic acid, and response to steroid pulse therapy. Intern Med 1995; 34: 424-9.
99. Brown WT, Zebrower M, Kieras FJ. Progeria, a model disease for the study of accelerated aging. In: Woodhead AD, Blackett AD, Hollaender A, eds. Molecular Biology of Aging. New York: Plenum Press, 1985: 375-96.
100. Nakamura T, Takagaki K, Kubo K, et al. Hyaluronate synthesized by cultured skin fibroblasts derived from patients with Werner's syndrome. Biochim Biophys Acta 1992; 1139: 84-90.
101. Bjermer L, Engström-Laurent A, Lundgren R, Rosenhall L, Hällgren R. Hyaluronate and type III procollagen peptide concentrations in bronchoalveolar lavage fluid as markers of disease activity in farmer's lung. BMJ 1987; 295: 803-6.
102. Milman N, Kristensen MS, Bentsen K, Grode G, Frederiksen J. Hyaluronan and procollagen type III aminoterminal peptide in serum and bronchoalveolar lavage fluid in patients with pulmonary sarcoidosis. Sarcoidosis 1995; 12: 38-41.
103. Lavö B, Knutson L, Lööf L, Odlind B, Hällgren R. Signs of increased leakage over the jejunal mucosa during gliadin challenge of patients with coeliac disease. Gut 1990; 31: 153-7.
104. Lundin Å, Engström-Laurent A, Michaëlsson G, Tengblad A. High levels of hyaluronate in suction blister fluid from active psoriatic lesions. Br J Dermatol 1987; 116: 335-40.
105. Edelstam GAB, Lundkvist Ö, Venge P, Laurent TC. Hyaluronan and myeloperoxidase in human peritoneal fluid during genital inflammation. Inflammation 1994; 18: 13-21.
106. Laurent UBG, Laurent TC, Hellsing LK, Persson L, Hartman M, Lilja K. Hyaluronan in human cerebrospinal fluid (submitted).
107. Berg S, Brodin B, Hesselvik F, Laurent TC, Maller R. Elevated levels of plasma hyaluronan in septicaemia. Scand J Clin Lab Invest 1988; 48: 727-32.
108. Berg S. Hyaluronan in Sepsis. A Clinical and Experimental Study. Linköping University Medical Dissertations, Linköping 1994; no. 424.
109. Hällgren R, Samuelsson T, Laurent TC, Modig J. Accumulation of hyaluronan (hyaluronic acid) in the lung in adult respiratory distress syndrome. Am Rev Respir Dis 1989; 139: 682-7.
110. 2 removal. Eur J Clin Chem Clin Biochem 1991; 29: 805-12.
111. Rao PN, Zeevi A, Snyder J, et al. Monitoring of acute lung rejection and infection by bronchoalveolar lavage and plasma levels of hyaluronic acid in clinical lung transplantation. J Heart Lung Transplant 1994; 13: 958-62.
112. Adler G, Kropf J, Grobe E, Gressner AM. Follow-up of serum levels of extracellular matrix components in acute and chronic pancreatitis. Eur J Clin Invest 1990; 20: 494-501.
113. Löhr M, Spies B, Heptner B, Domschke S, Hahn EG. Parameter des Bindegewebesstoffwechsels als Marker bei akuter und chronischer Pankreatitis. Z Gastroenterol 1991; 29: 231-6.
114. Lebel L. Turnover of Circulating Hyaluronan. Studies in Man and Experimental Animals. Acta Universitatis Upsaliensis. Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine, Uppsala, 1989; no. 217.
115. Pertoft H, Alston-Smith J, Fraser JRE, Laurent TC. Hyaluronan accumulates around portal vessels in liver after endotoxin treatment of rats. J Endotoxin Res 1995; 2: 281-7.
116. Berg S, Jansson I, Hesselvik FJ, Laurent TC, Lennquist S, Walther S. Hyaluronan: relationship to hemodynamics and survival in porcine injury and sepsis. Crit Care Med 1992; 20: 1315-21.
117. Rasmussen I, Lebel L, Arvidsson D, Haglund U, Laurent TC, Gerdin B. Hepatic extraction of hyaluronic acid in porcine peritonitis. Eur Surg Res 1995; 27: 1-10.
118. Deaciuc IV, Bagby GJ, Lang CH, Skrepnik N, Spitzer JJ. Gram-negative bacterial lipopolysaccharide impairs hyaluronan clearance in vivo and its uptake by the isolated, perfused rat liver. Hepatology 1993; 18: 173-8.
119. Hällgren R, Engström-Laurent A, Nisbeth U. Circulating hyaluronate. A potential marker of altered metabolism of the connective tissue in uremia. Nephron 1987; 46: 150-4.
120. Honkanen E, Fröseth B, Grönhagen-Riska C. Serum hyaluronic acid and procollagen III amino terminal propeptide in chronic renal failure. Am J Nephrol 1991; 11: 201-6.
121. Turney JH, Davison AM, Forbes MA, Cooper EH. Hyaluronic acid in end-stage renal failure treated by haemodialysis: clinical correlates and implications. Nephrol Dial Transplant 1991; 6: 566-70.
122. Ozasa H, Chichibu K, Tanaka Y, Kondo T, Kitajima K, Ota K. Relationship between plasma levels of hyaluronic acid and amyloid-associated osteoarthropathy in chronic hemodialysis patients. Nephron 1992; 61: 187-91.
123. Jouzeau JY, Chary-Valckenaere I, Cao-Huu T, et al. Elevated circulating levels of hyaluronan in long-term hemodialysis patients with dialysis-associated arthropathy: what does it mean? Nephron 1993; 64: 498-9.
124. Lipkin GW, Forbes MA, Cooper EH, Turney JH. Hyaluronic acid metabolism and its clinical significance in patients treated by continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 1993; 8: 357-60.
125. Takasu S, Takatsu S, Kunitomo K, Kokumai Y. Serum hyaluronic acid and interleukin-6 as possible markers of carpal tunnel syndrome in chronic hemodialysis patients. Artif Organs 1994; 18: 420-4.
126. Onarheim H, Reed RK, Laurent TC. Elevated hyaluronan blood concentrations in severely burned patients. Scand J Clin Lab Invest 1991; 51: 693-7.
127. Onarheim H, Missavage AE, Gunther RA, Kramer GC, Reed RK, Laurent TC. Marked increase of plasma hyaluronan after major thermal injury and infusion therapy. J Surg Res 1991; 50: 259-65.
128. Berg S, Hesselvik JF, Laurent TC. Influence of surgery on serum concentrations of hyaluronan. Crit Care Med 1994; 22: 810-4.
129. Berg S, Engman A, Hesselvik JF, Laurent TC. Crystalloid infusion increases plasma hyaluronan. Crit Care Med 1994; 22: 1563-7.
130. Deutsch HF. Some properties of a human serum hyaluronic acid. J Biol Chem 1957; 224: 767-74.
131. Tomasi TB Jr, Van B, Robertson W, Naeye R, Reichlin M. Serum hyperviscosity and metabolic acidosis due to circulating hyaluronic acid. J Clin Invest 1966; 45: 1080-1.
132. Morse BS, Nussbaum M. The detection of hyaluronic acid in the serum and urine of a patient with nephroblastoma. Am J Med 1967; 42: 996-1002.
133. Allerton SE, Beierle JW, Powars DR, Bavetta LA. Abnormal extracellular components in Wilms' tumor. Cancer Res 1970; 30: 679-83.
134. Broughton PMG, Dykes JRW, Holt S, Ridley JW, Steel AE. Mucopolysaccharide in the blood of a patient with neuroblastoma. J Clin Pathol 1970; 23: 246-8.
135. Powars DR, Allerton SE, Beierle J, Butler BB. Wilms' tumor clinical correlation with circulating mucin in three cases. Cancer 1972; 29: 1597-605.
136. Hopwood JJ, Dorfman A. Glycosaminoglycan synthesis by Wilms' tumor. Pediat Res 1978; 12: 52-6.
137. Wu AHB, Parker OS, Ford L. Hyperviscosity caused by hyaluronic acid in serum in a case of Wilms' tumor. Clin Chem 1984; 30: 914-6.
138. Ater JL, Gooch WM, Bybee BL, O'Brien RT. Poor prognosis for mucin-producing Wilms' tumor. Cancer 1984; 53: 319-23.
139. Kimmel G. The nature of Wilms tumor mucins. Diss Abstr Int B 1979; 40: 37.
140. Kabat E. A polysaccharide in tumors due to a virus of leucosis and sarcoma of fowls. J Biol Chem 1939; 130: 143-7.
141. Bracey AW, Wu AHB, Aceves J, Chow T, Carlile S, Hoots WK. Platelet dysfunction associated with Wilms' tumor and hyaluronic acid. Am J Hematol 1987; 24: 247-57.
142. Kumar S, West DC, Ponting JM, Gattamaneni HR. Sera of children with renal tumours contain low-molecular-mass hyaluronic acid. Int J Cancer 1989; 44: 445-8.
143. Kumar S, West DC, Ponting JM. Hyaluronic acid and childhood renal tumours. J Natl Cancer Inst 1990; 82: 973-4.
144. Fraizer GE, Bowen-Pope DF, Vogel AM. Production of platelet-derived growth factor by cultured Wilms' tumor cells and fetal kidney cells. J Cell Physiol 1987; 133: 169-74.
145. Heldin P, Laurent TC, Heldin C-H. Effect of growth factors on hyaluronan synthesis in cultured human fibroblasts. Biochem J 1989; 258: 919-22.
146. Longaker MT, Adzick NS, Sadigh D, et al. Hyaluronic acid-stimulating activity in the pathophysiology of Wilms' tumors. J Natl Cancer Inst 1990; 82: 135-9.
147. Meyer K, Chaffee E. Hyaluronic acid in the pleural fluid associated with a malignant tumor involving the pleura and peritoneum. J Biol Chem 1940; 133: 83-91.
148. Roboz J, Greaves J, Sllides D, Chahinian AP, Holland JF. Hyaluronic acid content of effusions as a diagnostic aid for malignant mesothelioma. Cancer Res 1985; 45: 1850-4.
149. Frebourg T, Lerebours G, Delpech B, et al. Serum hyaluronate in malignant pleural mesothelioma. Cancer 1987; 59: 2104-7.
150. Dahl IMS, Laurent TC. Concentration of hyaluronan in the serum of untreated cancer patients with special reference to patients with mesothelioma. Cancer 1988; 62: 326-30.
151. Dahl IMS, Solheim ØP, Erikstein B, Müller E. A longitudinal study of the hyaluronan level in the serum of patients with malignant mesotnelioma under treatment. Cancer 1989; 64: 68-73.
152. Asplund T, Versnel MA, Laurent TC, Heldin P. Human mesothelioma cells produce factors that stimulate the production of hyaluronan by mesothelial cells and fibroblasts. Cancer Res 1993; 53: 388-92.
153. Delpech B, Bertrand P, Maingonnat C. Immunoenzymoassay of the hyaluronic acid-hyaluronectin interaction: application to the detection of hyaluronic acid in serum of normal subjects and cancer patients. Anal Biochem 1985; 149: 555-65.
154. Cooper EH, Forbes MA. Serum hyaluronic acid levels in cancer. Br J Cancer 1988; 58: 668-9.
155. Schuller J, Fogl U, Bosse Ch, Schernthaner G. Serum hyaluronic acid levels in cancer patients with different tumor types. Abstracts of the Sixth International Conference on Differentiation of Normal and Neoplastic Cells, Vancouver, Canada, July 29-August 2, 1990.
156. Delpech B, Chevallier B, Reinhardt N, et al. Serum hyaluronan (hyaluronic acid) in breast cancer patients. Int J Cancer 1990; 46: 388-90.
157. Ponting J, Howell A, Pye D, Kumar S. Prognostic relevance of serum hyaluronan levels in patients with breast cancer. Int J Cancer 1992; 52: 873-6.
158. Abildgaard N, Lanng Nielsen JL, Heickendorff L. Connective tissue components in serum in multiple myeloma: analyses of propeptides of type I and type III procollagens, type I collagen telopeptide and hyaluronan. Am J Hematol 1994; 46: 173-8.
159. Lohmander S, Saxne T, Heinegård D, eds. Molecular markers for joint and skeletal diseases: an Eric Fernström symposium. Acta Orthop Scand 1995; 66 (Suppl 266).
160. Guéchot J, Poupon RE, Poupon R. Serum hyaluronan as a marker of liver fibrosis. J Hepatol 1995; 22 (Suppl 2): 103-6.